ArticleThe journal of headache and pain2026

Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry.

S Ferrao-Malheiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.